0
ARTICLE |

Thrombolysis With Tissue-Type Plasminogen Activator in Acute Myocardial Infarction: Title and subTitle BreakPotentials and Pitfalls FREE

Allan S. Jaffe, MD; Burton E. Sobel, MD
[+] Author Affiliations

This article is one of a series sponsored by the American Heart Association.

Reprint requests to Washington University School of Medicine, 660 S Euclid, Box 8086, St Louis, MO 63110 (Dr Sobel).


JAMA. 1986;255(2):237-239. doi:10.1001/jama.1986.03370020083034
Text Size: A A A
Published online

RAPID dissemination of preliminary results of research may predispose the medical profession and the public to premature, ill-advised, or indiscriminate acceptance of allegedly therapeutic modalities before efficacy has been established. Objective evaluation of an intervention such as coronary thrombolysis may be obscured by excessive enthusiasm of advocates, undue cynicism of critics, media hype, and real or imagined competitive pressures impinging on the modern practitioner of medicine. In this article we shall consider, in this context, findings pertinent to coronary thrombolysis with conventional activators or tissue-type plasminogen activator (t-PA) in the treatment of acute myocardial infarction.

The concept that acute coronary thrombosis is responsible for myocardial infarction is not new. Initial attempts in 1959 by Sherry and associates were made to activate the fibrinolytic system in pilot studies of patients with acute infarction. Subsequently, 13 large-scale trials with intravenous streptokinase were performed in Europe and Scandinavia. Conflicting results ensued, in part

REFERENCES

Rentrop P, Blanke H, Karsch KR, et al:  Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris . Circulation 1981;;63:307-317.
DeWood MA, Spores J, Hensley GR, et al:  Coronary arteriographic findings in acute transmural myocardial infarction . Circulation 1983;; 68:I39-I49.
Shafer KE, Santoro SA, Sobel BE, et al:  Monitoring activity of fibrinolytic agents . Am J Med 1984;;76:879-886.
Tiefenbrunn AJ, Robison AK, Kurnik PB, et al:  Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology . Circulation 1985;;71:110-116.
Rentrop KP:  Thrombolytic therapy in patients with acute myocardial infarction . Circulation 1985;;71:627-631.
Van de Werf F, Ludbrook PA, Bergmann SR, et al:  Coronary thrombolysis with tissuetype plasminogen activator in patients with evolving myocardial infarction . N Engl J Med 1984;;310:609-613.
Collen D, Topol EJ, Tiefenbrunn AJ, et al:  Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized, placebo-controlled trial . Circulation 1984;;70:1012-1017.
The TIMI Study Group:  The thrombolysis in myocardial infarction (TIMI) trial, phase I findings . N Engl J Med 1985;;312:932-936.
Bergmann SR, Lerch RA, Fox KAA, et al:  Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography . Am J Med 1982;;73:573-581.
Sobel BE, Geltman EM, Tiefenbrunn AJ, et al:  Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase . Circulation 1984;;69:983-989.
Sheehan FH, Mathey DG, Schofer J, et al:.  Factors that determine recovery of left ventricular function after thrombolysis in patients with acute myocardial infarction . Circulation 1985;; 71:1121-1128.
Kennedy JW, Ritchie JL, Davis KB, et al:  The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction . N Engl J Med 1985;;312:1073-1078.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Rentrop P, Blanke H, Karsch KR, et al:  Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris . Circulation 1981;;63:307-317.
DeWood MA, Spores J, Hensley GR, et al:  Coronary arteriographic findings in acute transmural myocardial infarction . Circulation 1983;; 68:I39-I49.
Shafer KE, Santoro SA, Sobel BE, et al:  Monitoring activity of fibrinolytic agents . Am J Med 1984;;76:879-886.
Tiefenbrunn AJ, Robison AK, Kurnik PB, et al:  Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology . Circulation 1985;;71:110-116.
Rentrop KP:  Thrombolytic therapy in patients with acute myocardial infarction . Circulation 1985;;71:627-631.
Van de Werf F, Ludbrook PA, Bergmann SR, et al:  Coronary thrombolysis with tissuetype plasminogen activator in patients with evolving myocardial infarction . N Engl J Med 1984;;310:609-613.
Collen D, Topol EJ, Tiefenbrunn AJ, et al:  Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized, placebo-controlled trial . Circulation 1984;;70:1012-1017.
The TIMI Study Group:  The thrombolysis in myocardial infarction (TIMI) trial, phase I findings . N Engl J Med 1985;;312:932-936.
Bergmann SR, Lerch RA, Fox KAA, et al:  Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography . Am J Med 1982;;73:573-581.
Sobel BE, Geltman EM, Tiefenbrunn AJ, et al:  Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase . Circulation 1984;;69:983-989.
Sheehan FH, Mathey DG, Schofer J, et al:.  Factors that determine recovery of left ventricular function after thrombolysis in patients with acute myocardial infarction . Circulation 1985;; 71:1121-1128.
Kennedy JW, Ritchie JL, Davis KB, et al:  The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction . N Engl J Med 1985;;312:1073-1078.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.